Aurinia Pharmaceuticals (AUPH) director receives 23,931 share option grant

Rhea-AI Filing Summary

Aurinia Pharmaceuticals Inc. reported that director Tina Susan Nova received a grant of stock options. The award covers 23,931 options to purchase common shares at an exercise price of $15.67 per share and is treated as a compensation grant, not a market purchase.

The options vest in full one year from the grant date and expire on June 4, 2036. Following this grant, Nova holds 23,931 derivative securities directly in the form of these options.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Nova Tina Susan

Role null

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)	23,931	$0.00	--

Holdings After Transaction: Director Stock Option (right to buy) — 23,931 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 23,931 options Exercise price: $15.67 per share Total derivative holdings after grant: 23,931 options +1 more

4 metrics

Options granted 23,931 options Director grant on June 4, 2026

Exercise price $15.67 per share Director stock option grant

Total derivative holdings after grant 23,931 options Held directly following transaction

Option expiration date June 4, 2036 Director option grant term

Key Terms

Director Stock Option (right to buy), grant/award acquisition, exercise price, expiration date

4 terms

Director Stock Option (right to buy) financial

"security_title: Director Stock Option (right to buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

exercise price financial

"conversion_or_exercise_price: 15.6700"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-04T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nova Tina Susan

(Last) (First) (Middle)

#140, 14315-118 AVENUE

(Street)

EDMONTON T5L 4S6

(City) (State) (Zip)

ALBERTA, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aurinia Pharmaceuticals Inc. [ AUPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$15.67	06/04/2026		A		23,931		(1)	06/04/2036	Common Shares	23,931	$0	23,931	D

Explanation of Responses:

1. The options shall vest one year from date of grant.

Remarks:

	/s/ Tina Nova	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Aurinia Pharmaceuticals (AUPH) disclose in this Form 4 filing?

Aurinia Pharmaceuticals disclosed that director Tina Susan Nova received a grant of 23,931 stock options. These options give her the right to buy common shares at $15.67 per share as part of her director compensation, not an open-market trade.

How many Aurinia (AUPH) stock options were granted to director Tina Susan Nova?

Tina Susan Nova was granted 23,931 stock options. Each option represents the right to purchase one common share of Aurinia Pharmaceuticals at a fixed exercise price, providing potential future ownership if exercised after vesting conditions are met.

What is the exercise price and term of the Aurinia (AUPH) director stock options?

The granted options have an exercise price of $15.67 per share and an expiration date of June 4, 2036. This long-dated option term gives the director an extended window to exercise the options once they have vested.

When do Tina Susan Nova’s Aurinia (AUPH) stock options vest?

The options granted to Tina Susan Nova vest one year from the grant date. This means she must remain eligible through that one-year period before she can exercise the options to purchase Aurinia common shares at the fixed exercise price.

Did the Aurinia (AUPH) director buy or sell common shares in this transaction?

No common shares were bought or sold in this transaction. The Form 4 reports a compensation-related grant of stock options, classified as a grant or award acquisition, rather than an open-market purchase or sale of Aurinia common shares.